Paul Sondel, MD, PhD, was recently awarded $29,523 for his project, “Destruction of Neuroblastoma via Synapse Formation with the Novel Therapeutic Immunocytokine: hu14.18-IL2” through “Abbie’s Fund” Foundation. This research will assist in the development of clinically relevant strategies to improve the anti-tumor efforts of hu14.18-IL2 (an anti-neuroblastoma antibody).